In T2D with ASCVD/high CV risk, SGLT2i reduced HF hospitalization/event when compared to incretin-based therapies (HR 0.78, 95% CI 0.70–0.87), with no significant difference when compared to finerenone (HR 0.90, 95% CI 0.75–1.07) or between incretin-based therapies and finerenone (HR 1.15, 95% CI 0.95–1.38). Here, GCG is linked to hydrops fetalis.